Compare MLCO & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | BHVN |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | 274 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2006 | 2022 |
| Metric | MLCO | BHVN |
|---|---|---|
| Price | $5.32 | $15.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $10.10 | ★ $29.08 |
| AVG Volume (30 Days) | 1.5M | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.07 | $7.48 |
| 52 Week High | $10.15 | $18.57 |
| Indicator | MLCO | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 58.31 |
| Support Level | $5.13 | $8.69 |
| Resistance Level | $5.73 | $16.60 |
| Average True Range (ATR) | 0.17 | 1.12 |
| MACD | -0.03 | 0.24 |
| Stochastic Oscillator | 33.83 | 55.92 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.